Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05699018
Other study ID # 2022-A02148-35
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 13, 2023
Est. completion date December 15, 2025

Study information

Verified date May 2024
Source University Hospital, Angers
Contact William BELLANGER, PH
Phone 02 41 73 58 10
Email william.bellanger@univ-angers.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective of the SOPRANO study is to compare two blood fibrosis tests, the eLIFT and the FibroMeter, for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers.


Description:

Chronic liver diseases (CLD) are responsible for 17 000 deaths each year in France (cirrhosis: 8 000, liver cancer: 9 000). Non-alcoholic fatty liver disease (NAFLD) and alcoholic liver disease (ALD) are the two main causes of CLD in France, affecting respectively 25% and 12% of the adult general population. A subset of these patients develops advanced liver fibrosis (ALF), which requires referral to the specialist for specific evaluation and management to avoid the occurrence of cirrhosis and its life-threatening complications. General practitioners (GPs) are the first-line physicians in front of the large population of NAFLD and/or ALD patients. It is very difficult for GPs to identify the patients who develop ALF and require referral to the specialist, as their physical examination, usual biology and ultrasonography remain normal. The non-invasive diagnosis of liver fibrosis is now available with elastography devices and blood tests. Elastography is a very accurate method but it is available only in few specialised centers. Specialised blood tests are available to all physicians, but they are quite expensive and not reimbursed with therefore limited use in clinical practice. Consequently, liver fibrosis remains unevaluated in most patients with NAFLD and/or ALD, which explains why a lot are too late diagnosed at the stage of cirrhosis complications with poor short-term survival. The eLIFT isa new blood fibrosis test specifically dedicated for GPs with simple parameters and easy "by head" calculation. The simple eLIFT was compared with the specialised blood test FibroMeter for the diagnosis of ALF in an cohort of 1024 biopsy-proven NAFLD and/or ALD patients. eLIFT was little less accurate than FibroMeter (AUROC: 0.78 vs 0.81). Using the recommended cut-offs (eLIFT ≥8, FibroMeter ≥0.46), eLIFT was more sensitive than FibroMeter (86% vs 77%), whereas FibroMeter was highly more specific (71% vs 51%). These results position eLIFT and FibroMeter as interesting tools for the screening of ALF in large populations. As the preliminary results come from very selected patients, i.e. patients from tertiary centers who underwent a liver biopsy, it's necessary nox to evaluate in the real condition of primary care setting whether the use of eLIFT or FibroMeter will help GPs to screen ALF in their asymptomatic NAFLD and ALD patients.


Recruitment information / eligibility

Status Recruiting
Enrollment 1788
Est. completion date December 15, 2025
Est. primary completion date May 15, 2025
Accepts healthy volunteers No
Gender All
Age group 40 Years to 80 Years
Eligibility Inclusion Criteria: - NAFLD and/or ALD patient defined by at least 1 of the following criteria: - Excessive alcohol consumption: higher than 210 g / week (men), or 140 g / week (women) - Type 2 diabetes - at least 2 metabolic factors among BMI higher than or equal to 25 kg / m 2; Elevated blood pressure (antihypertensive drug, or systolic blood pressure higher than or equal to 130mmHg, or diastolic blood pressure higher than or equal to 85mmHg), Dyslipidemia (lipid-lowering drug, or HDL cholesterol lower to 40mg/dl (men) / 50mg/dl (women), or triglycerides higher than or equal to150mg/dl); Hyperferritinemia (higher than upper limit of normal from the laboratory) - Bright liver at ultrasonography without steatosis-inducing drug(systemic corticosteroids, tamoxifen, amiodarone, methotrexate) - Patient's agreement to have a blood sample collected in a local laboratory participating in the study - Subjects covered by or having the rights to medical care assurance - Written informed consent obtained from subject Exclusion Criteria: - Already ongoing specialized follow-up for a chronic liver disease - Altered health status with poor short-term prognosis, not compatible with a screening procedure - Decompensated cirrhosis (hepatic encephalopathy, jaundice, ascites, variceal bleeding, hepatorenal syndrome) - Acute infection - Pregnancy, breastfeeding - Persons in detention by judicial or administrative decision - Person admitted to a health or social establishment for purposes other than research - Person subject to a legal protection measure - Person unable to express consent

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
eLIFT
Diagnostic procedure: elastography devices, blood tests (e-LIFT + Fibrometer), liver biopsy if necessary (elastometry = 8 kPa and < 15 kPa)

Locations

Country Name City State
France ANGERS Angers
France CHU Angers Angers
France BECON Bécon-les-Granits
France Chalonnes Chalonnes-sur-Loire
France COMBOURG Combourg
France LIFFRE Liffré
France Montreuil Montreuil-Bellay
France CHU Rennes Rennes
France RENNES - Armagnac, Churchill Rennes
France RENNES - Kennedy Rennes
France SEGRE Segré
France Val Couesnon Val-Couesnon

Sponsors (1)

Lead Sponsor Collaborator
University Hospital, Angers

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Sensitivity of the eLIFT test for advanced liver fibrosis Rate of patients with advanced liver fibrosis correctly identified by the eLIFT test 1 day
Primary Sensitivity of the Fibrometer test for advanced liver fibrosis Rate of patients with advanced liver fibrosis correctly identified by the Fibrometer test 1 day
Secondary rate of patients referred to the specialist following the screening procedure, with eLIFT test Rate of patients with positive screening test (eLIFT =8) 1 day
Secondary rate of patients referred to the specialist following the screening procedure, with FibroMeter test Rate of patients with positive screening test (FibroMeter =0.46) 1 day
Secondary Rate of "unnecessary referrals" to the specialist with eLIFT test Rate of patients with positive screening test (eLIFT =8) but without final diagnosis of ALF 1 month
Secondary Rate of "unnecessary referrals" to the specialist with Fibrometer test Rate of patients with positive screening test (FibroMeter =0.46) but without final diagnosis of ALF 1 month
Secondary Number of hepatocellular carcinoma adetected following the screening procedure, with comparison between eLIFT and FibroMeter strategies Number of patients with hepatocellular carcinoma (diagnosed on MRI by the recommended radiological criteria: hyperenhancement on the arterial phase and washout on the portal venous phase, or by liver biopsy); 1 month
Secondary Number of gastroesophageal varices at risk of bleeding detected following the screening procedure, with comparison between eLIFT and FibroMeter strategies Number of patients with gastroesophageal varices at risk of bleeding (diagnosed by upper-gastrointestinal endoscopy: medium-large varices or small varices with red wall marks) 1 month
Secondary directs costs by type of disease such as ALF, hepatocellular carcinoma, gastroesophageal varices at risk of bleeding with comparison between eLIFT and FibroMeter strategies Mean direct cost per patient; mean direct cost generated to detect one patient with ALF, one patient with hepatocellular carcinoma, one patient with gastroesophageal varices at risk of bleeding 1 month
Secondary eLIFT and FibroMeter screening procedures as a function of the cause of the underlying liver disease (NAFLD, ALD, or mixed NAFLD+ALD) Rate of patient with ALF, positive screening test, hepatocellular carcinoma, gastroesophageal varices at risk of bleeding, and mean cost, with comparison between NAFLD, ALD, and mixed NAFLD+ALD subgroups 1 month
Secondary the accuracy of a sequential strategy using eLIFT as first-line test and FibroMeter as second-line test Rate of patients with ALF diagnosed by a stepwise algorithm using eLIFT =8 then, if positive, FibroMeter =0.46 1 day
Secondary patient adherence to the screening of advanced liver fibrosis Rate of patients included in the study who did not achieve the required screening procedures 1 month
Secondary most relevant risk factor of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care Risk factors among clinical characteristics, alcohol consumption, metabolic parameters independently associated with ALF diagnosis 1 day
Secondary specialized blood test ELF for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers Same endpoints than primary and secondaries 1 to 11, but using the recommended 9.8 threshold for ELF 1 day
Secondary Camden and Islington pathway (FIB4 then ELF) for the screening of advanced liver fibrosis in patients with NAFLD and/or ALD from primary care centers, Same endpoints than primary and secondaries 1 to 11, but using using the Camden and Islington pathway 1 day
Secondary Camden and Islington pathway , with comparison of sequential strategy eLIFT then FibroMeter Same endpoints than primary and secondaries 1 to 11, but using using the Camden and Islington pathway 1 day
See also
  Status Clinical Trial Phase
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Recruiting NCT06051669 - Comparison of iLivTouch and FibroScan for the Assessment of Liver Fibrosis and Steatosis in Adult Patients in the US
Completed NCT06244550 - Clinical Trials Using HepatoKeeper Herbal Essentials to Treat Non-alcoholic Fatty Liver Disease and Metabolic Factors N/A
Recruiting NCT06098417 - Biomarkers in the Diagnosis and Prognosis of NAFLD
Not yet recruiting NCT03623360 - Functional MRI to Determine Severity of Cirrhosis
Recruiting NCT01965418 - A Clinical Evaluation on Traditional Chinese Medicine Diagnosis and Treatment Program Blocking and Reversing Hepatitis B-related Liver Fibrosis - a Randomized, Controlled, Double-blind, Multi-center Clinical Trial Phase 4
Not yet recruiting NCT01133184 - Improved Prevention of Perinatal Hepatitis B Transmission Phase 4
Completed NCT00043303 - Safety and Efficacy Study of Interferon Gamma-1b in Hepatitis C Patients With Liver Fibrosis or Cirrhosis Phase 2
Completed NCT03872024 - Performances Evaluation of New FibroScan Probes Dedicated to Morbidly Obese Patients N/A
Recruiting NCT05912179 - Prospective Single Centre Observational Study to Compare the Diagnostic Yield of Different Modalities of Liver Biopsy
Recruiting NCT04533828 - 68Ga-FAPI PET/CT in Liver Fibrosis Patients Early Phase 1
Completed NCT04573543 - The Role of Immune Semaphorins in NAFLD
Recruiting NCT03277651 - Noninvasive Diagnostic Platform for Liver Fibrosis and Portal Hypertension N/A
Completed NCT01707472 - Study of Simtuzumab in HIV and/or Hepatitis C- Infected Adults With Liver Fibrosis Phase 2
Completed NCT01810458 - Liver Fibrosis in Alpha-1 Antitrypsin Deficiency (Liver AATD)
Completed NCT02060162 - Antiretroviral Treatment Outcomes in HIV-HBV Co-infected Patients in Southern Africa
Completed NCT01934777 - Efficacy and Tolerance of Treatment With DHA, Choline and Vitamin E in Children With Non-alcoholic Steatohepatitis Phase 3
Completed NCT01988753 - Non-invasive Biomarkers of Fibrosis in Pediatric Liver Diseases
Completed NCT00049842 - Prevention of Disease Progress in Chronic Hepatitis C Patients With Liver Fibrosis (Study P02570AM2)(COMPLETED) Phase 3
Recruiting NCT06063785 - Multispectral Optoacoustic Tomography in Patients With Cystic Fibrosis